title: [Use of vildagliptin from an internal disease specialists point of view].
abstract: Dipeptidyl peptidase 4 inhibitors (DPP 4) are used as an oral hypoglycaemic agent in Type- 2 diabetic patients. From a clinical point of view the most important advantages of this preparation are improved diabetes compensation, significant reduction of hypoglycaemia risk compared with sulfonylurea derivatives, neutral weight profile and good GIT tolerance. Vildagliptin is a molecule from the group of DPP 4 inhibitors which is recently used in internal outpatient care.
authors.affiliation: Centrum diabetologie, Klinika diabetologie, Institut Klinicke a experimentalni mediciny, Praha.
authors.forename: R
authors.initials: R
authors.lastname: Kožnarová
mesh_terms: D000218:Adamantane / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D009570:Nitriles / Q000627:therapeutic use*; D011759:Pyrrolidines / Q000627:therapeutic use*; D000077597:Vildagliptin
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D009570:Nitriles; D011759:Pyrrolidines; D000077597:Vildagliptin; D000218:Adamantane